{"id":43038,"date":"2025-10-10T17:20:30","date_gmt":"2025-10-10T09:20:30","guid":{"rendered":"https:\/\/flcube.com\/?p=43038"},"modified":"2025-10-10T17:20:31","modified_gmt":"2025-10-10T09:20:31","slug":"novo-nordisk-to-acquire-akero-therapeutics-for-5-2-billion-secures-future-value-with-efruxifermin","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43038","title":{"rendered":"Novo Nordisk to Acquire Akero Therapeutics for $5.2\u202fBillion, Secures Future Value with Efruxifermin"},"content":{"rendered":"\n

Novo Nordisk A\/S (NYSE: NVO<\/a>)<\/strong> announced today that it will acquire Akero\u202fTherapeutics<\/strong> (NASDAQ: AKRO<\/a>) for up to USD\u202f5.2\u202fbillion<\/strong> in cash, marking a significant expansion of the drug\u2011maker\u2019s portfolio in the high\u2011growth field of metabolic disease therapeutics.<\/p>\n\n\n\n

Deal Highlights<\/h3>\n\n\n\n
    \n
  • Purchase Price<\/strong> \u2013 Akero shareholders will receive USD\u202f54.00 per share<\/strong> in cash at closing, plus a non\u2011transferable Contingent Value Right (CVR).<\/li>\n\n\n\n
  • CVR Details<\/strong> \u2013 Each CVR entitles the holder to USD\u202f6.00 per share<\/strong> upon full U.S. regulatory approval of efruxifermin (EFX)<\/strong> for compensated cirrhosis due to metabolic dysfunction\u2011associated steatohepatitis (MASH) by 30\u202fJune\u202f2031.<\/li>\n\n\n\n
  • Total Value<\/strong> \u2013 The upfront cash component approximates USD\u202f4.7\u202fbillion<\/strong>; the potential CVR payment could raise the total equity value to USD\u202f5.2\u202fbillion<\/strong> if the regulatory milestone is met.<\/li>\n<\/ul>\n\n\n\n

    Strategic Rationale<\/h3>\n\n\n\n
      \n
    • Portfolio Synergy<\/strong> \u2013 EFX is a best\u2011in\u2011class candidate for MASH, complementing Novo\u202fNordisk\u2019s leadership in GLP\u20111\u2011based therapies for obesity, type\u202f2 diabetes, and other metabolic disorders.<\/li>\n\n\n\n
    • Unmet Need<\/strong> \u2013 MASH is a rapidly progressing liver disease with limited approved treatments; EFX\u2019s mechanism\u2014an engineered, long\u2011acting fibroblast\u2011growth\u2011factor analogue\u2014targets the root\u2011causes of hepatic fibrosis and inflammation.<\/li>\n\n\n\n
    • Commercial Advantage<\/strong> \u2013 The acquisition positions Novo\u202fNordisk to offer a comprehensive metabolic\u2011disease solution, from weight\u2011management to liver\u2011health, strengthening its competitive moat in the specialty\u2011pharma market.<\/li>\n<\/ul>\n\n\n\n

      EFX Development Timeline<\/h3>\n\n\n\n
        \n
      • Current Phase<\/strong> \u2013 EFX is in Phase\u202f2b\/3 trials, with data expected in 2027.<\/li>\n\n\n\n
      • Regulatory Milestone<\/strong> \u2013 Full U.S. approval is required for the CVR to trigger the additional cash payment; Novo\u202fNordisk will pursue accelerated pathways where possible.<\/li>\n\n\n\n
      • Commercial Outlook<\/strong> \u2013 If approved, EFX could enter the U.S. market in the early 2030s, capturing an unmet segment of the growing MASH patient population.<\/li>\n<\/ul>\n\n\n\n

        Next Steps<\/h3>\n\n\n\n
          \n
        • Closing Conditions<\/strong> \u2013 The transaction is subject to customary regulatory and shareholder approvals.<\/li>\n\n\n\n
        • Integration<\/strong> \u2013 Novo\u202fNordisk will integrate Akero\u2019s clinical program and commercial assets into its existing metabolic\u2011disease pipeline.<\/li>\n\n\n\n
        • Communication<\/strong> \u2013 Novo\u202fNordisk will announce the definitive agreement and provide an updated timeline for the EFX regulatory strategy in a forthcoming investor briefing.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"

          Novo Nordisk A\/S (NYSE: NVO) announced today that it will acquire Akero\u202fTherapeutics (NASDAQ: AKRO) for…<\/p>\n","protected":false},"author":1,"featured_media":43041,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4378,4379,76,148,860],"class_list":["post-43038","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-akero-therapeutics","tag-nasdaq-akro","tag-nash","tag-novo-nordisk","tag-nyse-nvo"],"yoast_head":"\nNovo Nordisk to Acquire Akero Therapeutics for $5.2\u202fBillion, Secures Future Value with Efruxifermin - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novo Nordisk A\/S (NYSE: NVO) announced today that it will acquire Akero\u202fTherapeutics (NASDAQ: AKRO) for up to USD\u202f5.2\u202fbillion in cash, marking a significant expansion of the drug\u2011maker\u2019s portfolio in the high\u2011growth field of metabolic disease therapeutics.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=43038\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk to Acquire Akero Therapeutics for $5.2\u202fBillion, Secures Future Value with Efruxifermin\" \/>\n<meta property=\"og:description\" content=\"Novo Nordisk A\/S (NYSE: NVO) announced today that it will acquire Akero\u202fTherapeutics (NASDAQ: AKRO) for up to USD\u202f5.2\u202fbillion in cash, marking a significant expansion of the drug\u2011maker\u2019s portfolio in the high\u2011growth field of metabolic disease therapeutics.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=43038\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-10T09:20:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-10T09:20:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1011.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43038#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43038\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novo Nordisk to Acquire Akero Therapeutics for $5.2\u202fBillion, Secures Future Value with Efruxifermin\",\"datePublished\":\"2025-10-10T09:20:30+00:00\",\"dateModified\":\"2025-10-10T09:20:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43038\"},\"wordCount\":350,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43038#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1011.webp\",\"keywords\":[\"Akero\u202fTherapeutics\",\"NASDAQ: AKRO\",\"NASH\",\"Novo Nordisk\",\"NYSE: NVO\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43038#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43038\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=43038\",\"name\":\"Novo Nordisk to Acquire Akero Therapeutics for $5.2\u202fBillion, Secures Future Value with Efruxifermin - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43038#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43038#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1011.webp\",\"datePublished\":\"2025-10-10T09:20:30+00:00\",\"dateModified\":\"2025-10-10T09:20:31+00:00\",\"description\":\"Novo Nordisk A\\\/S (NYSE: NVO) announced today that it will acquire Akero\u202fTherapeutics (NASDAQ: AKRO) for up to USD\u202f5.2\u202fbillion in cash, marking a significant expansion of the drug\u2011maker\u2019s portfolio in the high\u2011growth field of metabolic disease therapeutics.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43038#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43038\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43038#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1011.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1011.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novo Nordisk to Acquire Akero Therapeutics for $5.2\u202fBillion, Secures Future Value with Efruxifermin\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43038#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk to Acquire Akero Therapeutics for $5.2\u202fBillion, Secures Future Value with Efruxifermin\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk to Acquire Akero Therapeutics for $5.2\u202fBillion, Secures Future Value with Efruxifermin - Insight, China's Pharmaceutical Industry","description":"Novo Nordisk A\/S (NYSE: NVO) announced today that it will acquire Akero\u202fTherapeutics (NASDAQ: AKRO) for up to USD\u202f5.2\u202fbillion in cash, marking a significant expansion of the drug\u2011maker\u2019s portfolio in the high\u2011growth field of metabolic disease therapeutics.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=43038","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk to Acquire Akero Therapeutics for $5.2\u202fBillion, Secures Future Value with Efruxifermin","og_description":"Novo Nordisk A\/S (NYSE: NVO) announced today that it will acquire Akero\u202fTherapeutics (NASDAQ: AKRO) for up to USD\u202f5.2\u202fbillion in cash, marking a significant expansion of the drug\u2011maker\u2019s portfolio in the high\u2011growth field of metabolic disease therapeutics.","og_url":"https:\/\/flcube.com\/?p=43038","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-10T09:20:30+00:00","article_modified_time":"2025-10-10T09:20:31+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1011.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=43038#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=43038"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novo Nordisk to Acquire Akero Therapeutics for $5.2\u202fBillion, Secures Future Value with Efruxifermin","datePublished":"2025-10-10T09:20:30+00:00","dateModified":"2025-10-10T09:20:31+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=43038"},"wordCount":350,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=43038#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1011.webp","keywords":["Akero\u202fTherapeutics","NASDAQ: AKRO","NASH","Novo Nordisk","NYSE: NVO"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=43038#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=43038","url":"https:\/\/flcube.com\/?p=43038","name":"Novo Nordisk to Acquire Akero Therapeutics for $5.2\u202fBillion, Secures Future Value with Efruxifermin - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=43038#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=43038#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1011.webp","datePublished":"2025-10-10T09:20:30+00:00","dateModified":"2025-10-10T09:20:31+00:00","description":"Novo Nordisk A\/S (NYSE: NVO) announced today that it will acquire Akero\u202fTherapeutics (NASDAQ: AKRO) for up to USD\u202f5.2\u202fbillion in cash, marking a significant expansion of the drug\u2011maker\u2019s portfolio in the high\u2011growth field of metabolic disease therapeutics.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=43038#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=43038"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=43038#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1011.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1011.webp","width":1080,"height":608,"caption":"Novo Nordisk to Acquire Akero Therapeutics for $5.2\u202fBillion, Secures Future Value with Efruxifermin"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=43038#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk to Acquire Akero Therapeutics for $5.2\u202fBillion, Secures Future Value with Efruxifermin"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1011.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43038","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43038"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43038\/revisions"}],"predecessor-version":[{"id":43042,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43038\/revisions\/43042"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/43041"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43038"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43038"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43038"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}